IB-001
Phase 1Small molecule
IB-001 is one of 18 small molecule programs targeting Chronic Hepatitis B Virus Infection. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Chronic Hepatitis B Virus Infection
#DrugCompanyPhaseTrials
1Emtriva
GileadApproved
Hepsera
GileadApproved
Virazole
CConrado Roberto Hoffmann Filho
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Alinia
RRomark Laboratories L.C.
Approved
Cerubidine
HHikma Pharmaceuticals LLC
Approved
Bepirovirsen
GSKPhase 2
PEG-IFNα
GileadPhase 2
VIR-3434
VVir Biotechnology, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IB-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- IIntegerBio